...
首页> 外文期刊>Methods and findings in experimental and clinical pharmacology >Comparison of antiemetic efficacy between single and repeat treatment with dexamethasone in patients receiving carboplatin-based combination chemotherapy.
【24h】

Comparison of antiemetic efficacy between single and repeat treatment with dexamethasone in patients receiving carboplatin-based combination chemotherapy.

机译:地塞米松单次治疗和重复治疗在接受卡铂为基础的联合化疗患者中的止吐效果比较。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A retrospective study was carried out to compare the preventive effects of single and repeat treatment with dexamethasone (DEX) on delayed nausea and emesis in patients who had received carboplatin (CBDCA)-based combination chemotherapy. Sixty-four patients were evaluated. Efficacy was assessed using the nausea and emesis score, food intake score and the requirement for antiemetic medication. These forward scores were categorized as three-grade during the first 5 days after chemotherapy. Acute nausea and emesis were well controlled in both groups on day 1. Mean values of the nausea and emesis score on day 3 evening and the food intake score on day 4 morning in the repeat-treatment group was 1.31 +/- 0.93 and 3.46 +/- 1.03, respectively, which were significantly better when compared with the single-treatment group (2.00 +/- 1.52; P = 0.028 and 2.79 +/- 1.12; P = 0.018, respectively). Multivariate logistic regression analysis revealed that less frequent dispensing of antiemetic medication was significantly associated with the repeat-treatment group (adjusted odds ratio, 0.153; 95% confidence interval, 0.026-0.734; P = 0.018). These results suggest that repeat-dose DEX may be more effective than single-dose DEX for the prevention of delayed nausea and emesis after CBDCA-based combination chemotherapy.
机译:进行了一项回顾性研究,以比较接受基于卡铂(CBDCA)的联合化疗的患者地塞米松(DEX)的单次和重复治疗对延迟的恶心和呕吐的预防作用。评价了64名患者。使用恶心,呕吐评分,食物摄入评分和止吐药物的需求量评估疗效。在化学疗法后的前5天内,这些前瞻分数被分为三级。两组的急性恶心和呕吐在第1天均得到良好控制。重复治疗组第3天晚上的恶心和呕吐评分平均值和第4天早晨的进食分数分别为1.31 +/- 0.93和3.46 + /-1.03,分别比单药治疗组好得多(2.00 +/- 1.52; P = 0.028和2.79 +/- 1.12; P = 0.018)。多元logistic回归分析显示,重复治疗组的止吐药物分配频率较低(调整比值比为0.153; 95%置信区间为0.026-0.734; P = 0.018)。这些结果表明,在基于CBDCA的联合化疗后,重复剂量DEX可能比单剂量DEX更有效,可预防延迟的恶心和呕吐。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号